Please assess the completion status of the following clinical trial:

Trial Title: A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with type 2 diabetes (T2D) ≥ 6 months according to the World Health Organization (WHO) classification.~* Treated with stable doses of a single OAM for at least 8 weeks prior to screening; the dose must be more than or equal to minimum maintenance dose.~* Have the following HbA1c result at screening.~  * Participants taking DPP-4i: ≥7.5% and ≤9.5%,~ * Participants taking another OAM: ≥8.0% and ≤10.0%~* Stable body weight for at least 8 weeks prior to screening or not changed by more than 5 % in the past 8 weeks~* Have a body mass index (BMI) ≥18.5 kilogram/square meter (kg/m²) and \<35 kg/m² at Day 1.~Exclusion Criteria:~* Have type 1 diabetes (T1D)~* Have a history of ≥1 episode of ketoacidosis or hyperosmolar state/coma~* Have had any myocardial infarction (MI), heart failure or cerebrovascular accident (stroke)~* Have a known clinically significant gastric empty abnormality~* Have acute or chronic hepatitis~* Have had chronic or acute pancreatitis~* Have any self or family history of type 2A or type 2B multiple endocrine neoplasia in the absence of known C-cell hyperplasia~* Have any self or family history of medullary C-cell hyperplasia, focal hyperplasia, or carcinoma (including sporadic, familial, or part of Multiple endocrine neoplasia (MEN) 2A or 2B syndrome)~* Have evidence of significant, active autoimmune abnormality~* Have evidence of significant, uncontrolled endocrine abnormality~* Have active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer) for less than 5 years~* Have any hematologic condition that may interfere with HbA1c measurement

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dulaglutide 1.5 milligram (mg) (Type: EXPERIMENTAL): Participants received 1.5 mg of dulaglutide given weekly subcutaneously (SC) during the 52-week treatment period. Dulaglutide will be given alone or in combination with 1 oral antihyperglycemic medication (OAM). Participants on dipeptidyl peptidase-4 inhibitors (DPP-4i) discontinued DPP-4i at randomization and was regarded as monotherapy of dulaglutide, other OAMs continued at same dose during study period and were regarded as combination therapy with dulaglutide.
- Dulaglutide 0.75 mg (Type: ACTIVE_COMPARATOR): Participants received 0.75 mg of dulaglutide given weekly SC during the 52-week treatment period. Dulaglutide will be given alone or in combination with 1 OAM. Participants on DPP-4i discontinued DPP-4i at randomization and was regarded as monotherapy of dulaglutide, other OAMs continued at same dose during study period and were regarded as combination therapy with dulaglutide.

Based on this trial design, predict the completion outcome and termination type (if applicable).